NYSE: OGEN - Oragenics, Inc.

Rentabilité sur six mois: -43.31%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Oragenics, Inc.


À propos de l'entreprise Oragenics, Inc.

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.

plus de détails
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

IPO date 2004-02-25
ISIN US6840233026
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.oragenics.com
Цена ао 0.2462
Changement de prix par jour: -7.65% (0.234)
Changement de prix par semaine: -16.88% (0.26)
Changement de prix par mois: -22.82% (0.28)
Changement de prix sur 3 mois: -52.35% (0.4535)
Changement de prix sur six mois: -43.31% (0.3812)
Changement de prix par an: -84.99% (1.44)
Evolution du prix sur 3 ans: -39.64% (0.358)
Evolution du prix sur 5 ans: -58.95% (0.5264)
Evolution des prix depuis le début de l'année: -33.51% (0.325)

Sous-estimation

Nom Signification Grade
P/S 315.47 1
P/BV -13.5 0
P/E 0 0
EV/EBITDA -0.2201 0
Total: 2.75

Efficacité

Nom Signification Grade
ROA, % -328.26 0
ROE, % -714.95 0
Total: 1.67

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0.1886

Devoir

Nom Signification Grade
Debt/EBITDA -0.0311 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -95.99 0
Rentabilité Ebitda, % -60.16 0
Rentabilité EPS, % -94.31 0
Total: 0



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Charles L. Pope CPA Executive Chairman 1952 (73 année)
Mr. Joseph Michael Redmond President & Interim Principal Executive Officer 1961 (64 année)
Ms. Janet Huffman CFO, Secretary & Treasurer 1972 (53 année)
Dr. James P. Kelly M.A., M.D. Chief Medical Officer & Member of Scientific Advisor
Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. Chief Clinical Officer

Adresse: United States, Tampa, 4902 Eisenhower Boulevard - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.oragenics.com